This company is currently in Phase 3 of a pre treatment autoimmune therapy drug multikine that is aiming to improve your chances of chemo therapy by 10%. Results are expected within the next 6-12 months. And it could really hit a home run on the back of Phase 3 results. In the short term I expect investors to start taking bets and a test of the 10 level once broken will ultimately lead to a target of 12. Lots of upside. LONG